Efficacy of repeated intravitreal Lucentis (Ranibizumab) injection according to the genotypic characteristics of exudative age-related macular degeneration in Koreans

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0002531

Enrollment

300

Registered

2017-11-10

Start date

2010-10-12

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Before starting treatment, peripheral blood is obtained from each patient. All patients receive a loading dose of three monthly injections of Lucentis® (month 0, 1, 2), and are followed-up mont

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. An age over 50 years 2. Exudative age-related macular degeneration patients with subfoveal leakage on fluorescein angiogram (FA) and exudative change on OCT who are treated with intravitreal anti-VEGF injections 3. Agreement to genetic analysis

Exclusion criteria

Exclusion criteria: 1. any previous treatment for exudative age-related macular degeneration such as laser photocoagulation, PDT, or anti-VEGF injection; 2. other concomitant ocular disease such as diabetic retinopathy, retinal vascular disease, epiretinal membrane, and high myopia; 3. previous vitreoretinal surgery; and (4) presence of a disciform macular scar or atrophy.

Design outcomes

Primary

Measure	Time frame
Change of central macular thickness	—

Secondary

Measure	Time frame
Genotypic association with visual and anatomic outcome measures	—

Countries

Korea, Republic of

Contacts

Public ContactUn Chul Park

Seoul National University Hospital

cloudyfe@hanmail.net+82-2-2072-2438

Outcome results